FDA Approves Combination NSAID/Opioid Seglentis
October 21, 2021
2 MIN READOn October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
2021 mPower Virtual Conference
On-Demand
The Mitchell | Genex | Coventry team looks forward to connecting with you at the 2021 mPower Conference, taking place virtually October 12–14, 2021.
Opioid Reduction Success
September 28, 2021
2 MIN READAASP Northeast Trade Show
Visit Us at the Exhibit Booth Northeast is an event that has been designed to specifically fit the
The Black Lives Matter Movement Is Changing Us for the Better
August 20, 2020
The first half of 2020 has been unprecedented. There has been some good, a lot of bad and even some ugly. But when I step back and think of one word that sums it all up, it is change. Looking back at where we were as recently as mid-February, our industry was slated for powerful growth and business-as-usual meant powering forward like any other year.
2020 mPower Virtual Conference
On-Demand
Over the past several months, the Mitchell | Genex teams have been closely monitoring the developments surrounding COVID-19 and the CDC’s recommended travel guidelines.
Beyond the Status Quo
September 23, 2019
We have been conditioned to expect that “best” equates to positive, desired results. Whether in sports, business or healthcare – we strive beyond good or better and desire the “best.” But implementing accepted status quo best practices doesn’t guarantee optimum results. History is scattered with epic examples of “best” induced stagnation or worse outcomes.